125 related articles for article (PubMed ID: 28089627)
21. Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population: An 8-year follow-up study.
Lu ZY; Shao Z; Li YL; Wulasihan M; Chen XH
World J Gastroenterol; 2016 Apr; 22(13):3663-9. PubMed ID: 27053858
[TBL] [Abstract][Full Text] [Related]
22. One-Year Neoadjuvant Endocrine Therapy in Breast Cancer.
Rusz O; Vörös A; Varga Z; Kelemen G; Uhercsák G; Nikolényi A; Ormándi K; Simonka Z; Kahán Z
Pathol Oncol Res; 2015 Sep; 21(4):977-84. PubMed ID: 25753983
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
24. Nonalcoholic fatty liver disease: a negative risk factor for colorectal cancer prognosis.
You J; Huang S; Huang GQ; Zhu GQ; Ma RM; Liu WY; Shi KQ; Guo GL; Chen YP; Braddock M; Zheng MH
Medicine (Baltimore); 2015 Feb; 94(5):e479. PubMed ID: 25654388
[TBL] [Abstract][Full Text] [Related]
25. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients.
Knoop AS; Bentzen SM; Nielsen MM; Rasmussen BB; Rose C
J Clin Oncol; 2001 Jul; 19(14):3376-84. PubMed ID: 11454885
[TBL] [Abstract][Full Text] [Related]
26. The alterations of serum FGF-21 levels, metabolic and body composition in early breast cancer patients receiving adjuvant endocrine therapy.
Akyol M; Alacacioglu A; Demir L; Kucukzeybek Y; Yildiz Y; Gumus Z; Kara M; Salman T; Varol U; Taskaynatan H; Oflazoglu U; Bayoglu V; Tarhan MO
Cancer Biomark; 2017; 18(4):441-449. PubMed ID: 28106545
[TBL] [Abstract][Full Text] [Related]
27. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
Nordenskjöld A; Fohlin H; Fornander T; Löfdahl B; Skoog L; Stål O
Breast Cancer Res Treat; 2016 Nov; 160(2):313-322. PubMed ID: 27722840
[TBL] [Abstract][Full Text] [Related]
28. The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease.
Zhang S; Du T; Zhang J; Lu H; Lin X; Xie J; Yang Y; Yu X
Lipids Health Dis; 2017 Jan; 16(1):15. PubMed ID: 28103934
[TBL] [Abstract][Full Text] [Related]
29. Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials.
Ross DT; Kim CY; Tang G; Bohn OL; Beck RA; Ring BZ; Seitz RS; Paik S; Costantino JP; Wolmark N
Clin Cancer Res; 2008 Oct; 14(20):6602-9. PubMed ID: 18927301
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
31. Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial.
Aihara T; Yokota I; Hozumi Y; Aogi K; Iwata H; Tamura M; Fukuuchi A; Makino H; Kim R; Andoh M; Tsugawa K; Ohno S; Yamaguchi T; Ohashi Y; Watanabe T; Takatsuka Y; Mukai H
Breast Cancer Res Treat; 2014 Nov; 148(2):337-43. PubMed ID: 25318924
[TBL] [Abstract][Full Text] [Related]
32. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
33. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial.
Bruno S; Maisonneuve P; Castellana P; Rotmensz N; Rossi S; Maggioni M; Persico M; Colombo A; Monasterolo F; Casadei-Giunchi D; Desiderio F; Stroffolini T; Sacchini V; Decensi A; Veronesi U
BMJ; 2005 Apr; 330(7497):932. PubMed ID: 15746106
[TBL] [Abstract][Full Text] [Related]
34. Sex differences in the impact of nonalcoholic fatty liver disease on cardiovascular risk factors.
Du T; Sun X; Yuan G; Zhou X; Lu H; Lin X; Yu X
Nutr Metab Cardiovasc Dis; 2017 Jan; 27(1):63-69. PubMed ID: 27956025
[TBL] [Abstract][Full Text] [Related]
35. Risk of fatty liver after long-term use of tamoxifen in patients with breast cancer.
Yoo JJ; Lim YS; Kim MS; Lee B; Kim BY; Kim Z; Lee JE; Lee MH; Kim SG; Kim YS
PLoS One; 2020; 15(7):e0236506. PubMed ID: 32730287
[TBL] [Abstract][Full Text] [Related]
36. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
37. Short sleep duration is a risk of incident nonalcoholic fatty liver disease: a population-based longitudinal study.
Okamura T; Hashimoto Y; Hamaguchi M; Obora A; Kojima T; Fukui M
J Gastrointestin Liver Dis; 2019 Mar; 28(1):73-81. PubMed ID: 30851175
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
39. Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance.
Elefsiniotis IS; Pantazis KD; Ilias A; Pallis L; Mariolis A; Glynou I; Kada H; Moulakakis A
Eur J Gastroenterol Hepatol; 2004 Jun; 16(6):593-8. PubMed ID: 15167162
[TBL] [Abstract][Full Text] [Related]
40. Use of tamoxifen with postsurgical irradiation may improve survival in estrogen and progesterone receptor-positive male breast cancer.
Fogh S; Hirsch AE; Langmead JP; Goldberg SI; Rosenberg CL; Taghian AG; Powell SN; Kachnic LA
Clin Breast Cancer; 2011 Mar; 11(1):39-45. PubMed ID: 21421521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
